MRVI vs. MRUS, FOLD, RNA, BHC, MOR, MLTX, TGTX, ARWR, CORT, and JANX
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Merus (MRUS), Amicus Therapeutics (FOLD), Avidity Biosciences (RNA), Bausch Health Companies (BHC), MorphoSys (MOR), MoonLake Immunotherapeutics (MLTX), TG Therapeutics (TGTX), Arrowhead Pharmaceuticals (ARWR), Corcept Therapeutics (CORT), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.
Merus (NASDAQ:MRUS) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
Maravai LifeSciences has a net margin of -47.81% compared to Maravai LifeSciences' net margin of -390.36%. Merus' return on equity of -4.28% beat Maravai LifeSciences' return on equity.
Merus currently has a consensus price target of $56.33, indicating a potential upside of 29.12%. Maravai LifeSciences has a consensus price target of $11.44, indicating a potential upside of 0.92%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Merus is more favorable than Maravai LifeSciences.
Merus has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500.
In the previous week, Merus had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Merus and 6 mentions for Maravai LifeSciences. Merus' average media sentiment score of 0.70 beat Maravai LifeSciences' score of 0.60 indicating that Maravai LifeSciences is being referred to more favorably in the news media.
Maravai LifeSciences has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
96.1% of Merus shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 4.6% of Merus shares are owned by company insiders. Comparatively, 0.2% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Merus received 267 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. However, 67.44% of users gave Maravai LifeSciences an outperform vote while only 65.52% of users gave Merus an outperform vote.
Summary
Merus and Maravai LifeSciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
